Prosecution Insights
Last updated: November 12, 2026
Application No. 17/670,278

Combination Treatment for Hematological Cancers

Final Rejection §103§112
Filed
Feb 11, 2022
Priority
Aug 02, 2016 — provisional 62/370,018 +3 more
Examiner
COPPINS, JANET L
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
GERON Corporation
OA Round
5 (Final)
72%
Grant Probability
Favorable
6-7
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
677 granted / 934 resolved
+12.5% vs TC avg
Strong +26% interview lift
Without
With
+26.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
49 currently pending
Career history
1011
Total Applications
across all art units

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Application Status Applicant's amendment and response, filed on June 10, 2026, has been reviewed by the examiner and entered of record in the file. Claims 18, 19, and 44 are amended. Claims 1, 3-13, 15, 42 and 43 are cancelled. Claim 47 is newly added. 4. Claims 16-17 and 20-22, drawn to a kit and a pharmaceutical composition thereof, remain withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, with traverse, there being no allowable generic or linking claim. 5. Claims 18, 19, and 44-47 are under examination with the elected species and are the subject of this office action. Information Disclosure Statement 6. The information disclosure statement (IDS) submitted on June 10, 2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner, please refer to the signed copy of Applicant’s PTO-1449 form, attached herewith. Previous Claim Rejections - 35 USC § 112(b) 7. Claims 1, 3-13, 18, 19, and 42-46 were previously rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. 8. Claims 1 and 3-13 were previously rejected as being indefinite because the preamble of said claims recites a method of treating a disorder rather than a subject, i.e., the preamble fails to recite a method of treating a subject in need of treatment. 9. Claims 1 and 3-13 are cancelled, therefore the previous obviousness rejection is withdrawn. 10. Claim 18 and 44-46 were previously rejected as being indefinite because the preamble of said claims recites a method of treating a disorder rather than a subject, i.e., the preamble fails to recite a method of treating a subject in need of treatment. 11. In view of Applicant’s amendment to incorporate the text “in a subject in need thereof” into the preamble, the previous indefiniteness rejections are overcome and are withdrawn. Previous Claim Rejections - 35 USC § 112(a) 12. Claims 1, 3-13, 42, and 43 were previously rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement, regarding the full scope of telomerase inhibitors and Bcl-2 inhibitors embraced by the claims. 13. In view of the cancellation of claims 1, 3-13, 42 and 43, the previous written description rejection is withdrawn. 14. Claims 1, 3-13, 42, and 43 were previously rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as lacking enablement for treating the full scope of hematological disorders or inducing apoptosis in any hematological cancer cell, comprising administering any telomerase inhibiting compound and any Bcl-2 inhibiting compound, as embraced by the claims. 15. In view of the cancellation of claims 1, 3-13, 42 and 43, the previous enablement rejection is withdrawn. Previous Claim Rejections - 35 USC § 103 16. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. 17. Claims 1, 3, 4, 7, 8, 10-13, 15, 18 and 42-46 were previously rejected under 25 U.S.C. 103 as being unpatentable over Kuo et al., Cell Stem Cell (2014), as evidenced by PubChem (https://pubchem.ncbi.nlm.nih.gov/compound/Imetelstat-sodium 2014), in view of Konapleva et al., Blood (2014), and further in view of Cantilena et al., (https://ashpublications.org/blood/article/126/23/1267/104593/Activity-of-the-Telomerase-Inhibitor-GRN163L 2015). 18. Claims 1, 3, 4, 7, 8, 10-13, and 15 are cancelled. 19. Thus, claims 18 and 42-46 remain rejected and claim 47 is newly rejected under 25 U.S.C. 103 as being unpatentable over Kuo et al., Cell Stem Cell (2014), as evidenced by PubChem (https://pubchem.ncbi.nlm.nih.gov/compound/Imetelstat-sodium 2014), in view of Konapleva et al., Blood (2014), and further in view of Cantilena et al., (https://ashpublications.org/blood/article/126/23/1267/104593/Activity-of-the-Telomerase-Inhibitor-GRN163L 2015). 20. This rejection is modified as necessitated by Applicant’s amendatory changes to claim 18. Claim 18, as amended, is directed to a method of treating acute myeloid leukemia in a subject in need thereof, comprising administering imetelstat or a pharmaceutically acceptable salt thereof (more specifically, imetelstat sodium (claim 47)), and ABT-199 to said subject having AML, wherein the imetelstat or a pharmaceutically acceptable salt thereof is administered at a dose of about 5 mg/kg to 30 mg/kg; and and the ABT-199 or a pharmaceutically acceptable salt thereof is administered at a dose of about 50-400 mg, daily, (claim 44); more specifically 400 mg daily (claim 45); or 100 mg/daily (claim 46). 21. Kuo et al. disclose the activity of the telomerase inhibitor imetelstat against acute myeloid leukemia (AML) cells in patient samples, i.e.: “imetelstat (GRN163L), a pharmacological telomerase inhibitor, showed significant activity against primary human AML cells… Administration of imetelstat prevented AML development in primary human xenografts and leukemia progression remained significantly delayed for weeks after suspension of treatment. Importantly, addition of imetelstat to chemotherapy reduced or delayed leukemia relapse compared to chemotherapy alone,” [emphasis added] (Page 2, third paragraph, lines 12-16). And, it is clear as evidenced by Pubchem that GRN163L is the sodium salt of imetelstat, (see under “Synonyms”). 22. Kuo et al. teach that telomerase deficiency in AML cells resulting from the administration of the telomerase inhibitor GRN163L is characterized by increased apoptosis, which meets the limitation of claim 10 (Page 2, second paragraph). Based on the teaching of Kuo et al, one skilled in the art before the effective filing date of the claimed invention would have been motivated to administer the known telomerase inhibitor imetelstat sodium to a subject having AML, and would have had a reasonable expectation of success that said administration would induce apoptosis of AML cells. Thus it would have been obvious to one skilled in the art before the effective filing date of the claimed invention to administer imetelstat sodium to a subject having AML, resulting in the successful treatment of AML in said subject in need thereof. 23. As such, Kuo et al. suggest treating AML in a subject by administering imetelstat sodium to a subject in need thereof, but do not teach the but do not teach the administration of ABT-199. 24. Yet, Konopleva et al. teach the administration of the orally bioavailable BCL-2 inhibitor ABT-199 to patients diagnosed with high-risk AML, wherein ABT-199 demonstrates “considerable clinical activity” (Page 1, Introduction and Page 3, Conclusions). Konopleva et al. teach daily dosage amounts that are within the range of 20-800 mg ABT-199 required by claims 44-46: “pts received 20 mg ABT-199 on Week (Wk) 1 Day 1, with daily escalation to a final target dose of 800 mg on Day 6 and daily thereafter,” (Page 2, first paragraph). A daily dose range of from 2o mg/day -800 mg/day fully embraces the daily dose of 400 mg required by claim 45, the dose of 100 mg daily required by claim 46, the daily dose of about 100-400 mg required by claim 44. And, dose regimen optimization is clearly a result effective parameter that a person of ordinary skill in the art would routinely optimize given the guidance of the prior art. The determination of known effective amounts of known active agents to be administered to treat the same disease (in this case, AML) is considered well in the competence level of an ordinary skilled artisan in pharmaceutical science, involving merely routine skill in the art. It has been held that it is within the skill in the art to select optimal parameters, such as amounts of ingredients, in a composition in order to achieve a beneficial effect. As Konopleva et al. teach a dosage regimen of ABT-199 that is used to treat AML, and how to gradually escaleate that dosage based on side effects/adverse events, the dosage amount is considered a result-effective variable. Thus, it would also have been obvious to have chosen a dosage from among those dose amounts known to be effective in methods of treating AML. 25. Kuo et al. do not teach the dosage amount of imetelstat or a pharmaceutically acceptable salt thereof. 26. Yet, Cantilena et al. teach the treatment of an AML cell line comprising administering imetelstat at dose amounts of 1.25 M, 2.5 M, 5 M, 10 M, 20 M and 40 M, which are equivalent to mg doses of 5.76 mg, 11.53 mg, 23.0 mg, 46.1 mg, 92.2 mg, and 184.4 mg, when converted to mg and using the molecular weight of imetelstat of 4610 g/moL, as evidenced by PubChem; (e.g., 4610 g/mol= 4,610,000 mg/mol; and 4,610,000 mg/mol x (1.25 mM/ 1,000,000= 0.00000125 mol)= 5.7625 mg). Thus, dose amounts of 5.76 mg, 11.53 mg, 23.0 mg, 46.1 mg, 92.2 mg, and 184.4 mg embrace a range of imetelstat doses of about 0.5 mg/kg- 9.4 mg/kg (assuming a 62 kg human) and overlap the range of from 5 mg/kg to about 30 mg/kg as required by claim 1. And, MPEP 2144.05 states: In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). Even a slight overlap in range establishes a prima facie case of obviousness. In re Peterson, 65 USPQ2d 1379, 1382 (Fed. Cir. 2003). And, "A prior art reference that discloses a range encompassing a somewhat narrower claimed range is sufficient to establish a prima facie case of obviousness." In re Peterson, 315 F.3d 1325, 1330, 65 USPQ2d 1379, 1382-83 (Fed. Cir. 2003). >See also In re Harris, 409 F.3d 1339, 74 USPQ2d 1951 (Fed. Cir. 2005). 27. As such, one skilled in the art before the effective filing date of the claimed invention would have been motivated to treat AML in a subject in need thereof by administering the combination of imetelstat or a pharmaceutically acceptable salt thereof in an amount of about 5 mg/kg to about 30 mg/kg, and ABT-199 in an amount of from 50-400 mg to treat AML to said subject, with a reasonable expectation of success. 28. It would have been obvious to one skilled in the art before the effective filing date of the claimed invention to administer said combination because each of imetelstat sodium and ABT-199 has previously demonstrated apoptosis against AML cells in vitro and activity against AML in vivo. And, the rationale to modify or combine the prior art does not have to be expressly stated in the prior art; the rationale may be expressly or impliedly contained in the prior art or it may be reasoned from knowledge generally available to one of ordinary skill in the art, established scientific principles, or legal precedent established by prior case law, please see In re Fine, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988); In re Jones, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). See also In re Kotzab, 217 F.3d 1365, 1370, 55 USPQ2d 1313, 1317 (Fed. Cir. 2000) (setting forth test for implicit teachings); In re Eli Lilly & Co., 902 F.2d 943, 14 USPQ2d 1741 (Fed. Cir. 1990) (discussion of reliance on legal precedent); In re Nilssen, 851 F.2d 1401, 1403, 7 USPQ2d 1500, 1502 (Fed. Cir. 1988) (references do not have to explicitly suggest combining teachings). Furthermore, MPEP 2144 teaches that the strongest rationale for combining references is a recognition, expressly or impliedly in the prior art or drawn from a convincing line of reasoning based on established scientific principles or legal precedent, that some advantage or expected beneficial result would have been produced by their combination. 29. In the instant case, two known compounds which individually demonstrate activity against AML could be combined in order to achieve an additive effect for treating AML in a subject, or to induce apoptosis in AML cells in vitro, with the expected result of successfully treating/ inhibiting the progression of AML. 30. Please refer to MPEP 2144.06 “I. COMBINING EQUIVALENTS KNOWN FOR THE SAME PURPOSE” wherein Kerkhoven is specifically referenced: “It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art.” In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980) (citations omitted) (Claims to a process of preparing a spray-dried detergent by mixing together two conventional spray-dried detergents were held to be prima facie obvious.). See also In re Crockett, 279 F.2d 274, 126 USPQ 186 (CCPA 1960) (Claims directed to a method and material for treating cast iron using a mixture comprising calcium carbide and magnesium oxide were held unpatentable over prior art disclosures that the aforementioned components individually promote the formation of a nodular structure in cast iron.); and Ex parte Quadranti, 25 USPQ2d 1071 (Bd. Pat. App. & Inter. 1992) (mixture of two known herbicides held prima facie obvious). 31. As stated by the Court in KSR International Co., v. Teleflex Inc., 127 US 1727 (2007), “when a patent ‘simply arranges old elements with each performing the same function it had been known to perform’ and yields no more than one would expect from such an arrangement, the combination is obvious” (quoting Sakraida v. AG Pro, Inc., 425 US 273 (1976); see also: Merck v. Biocraft (874 F.2d 804, 807 (Fed. Cir. 1989), indicating that it is a matter of obviousness for one of ordinary skill in the art to select a particular component from among many disclosed by the prior art as long as it is taught that the selection will result in the disclosed effect, even when the possible selections number 1200 or in the thousands; Sundance, Inc. v. DeMonte Fabricated, Ltd., 550 F.3d 1356 (Fed. Cir. 2008): a claimed invention is obvious is it is a combination of known prior art elements that would reasonably have been expected to maintain their respective properties or functions after they had been combined; Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327 (1945): indicating that “[r]eading a list and selecting a known component to meet known requirements is no more ingenious than selecting the last piece to put in the last opening in a jig-saw puzzle”; Wm. Wrigley Jr. Co. v. Cadbury Adams USA LLC, 683 F.3d 1356 (Fed. Cir. 2012): finding a “strong case of obviousness based on the prior art references of record [wherein the claim] recites a combination of elements that were all known in the prior art, and all that was required to obtain that combination was to substitute one well-known…agent for another”). 32. In the instant case, (1) each prior art element, imetelstat and ABT-199, performs the function specified in the claim, (i.e., treatment of AML or apoptosis of an AML cancer cell); (2) the claimed components (i.e., imetelstat and ABT-199) and their function(s) were known in the art; (3) a person of ordinary skill in the art would have recognized that combining the elements would achieve a greater than additive effect in the treatment of AML; and (4) the results of the combination would have been predictable (i.e., successful treatment of AML in a subject in need thereof). As such, claims 18 and 42-46 are prima facie obvious. Claim 19, as amended, is drawn to claim 18, and limits wherein the imetelstat or a pharmaceutically acceptable salt thereof is administered for 1, 2, 3, 4, 5, 6, 7, 8 or more than 8 dosage cycles, each cycle comprising: (a) intravenous administration of about 7 - 10 mg/kg imetelstat or a pharmaceutically acceptable salt thereof once every four weeks; (b) intravenous administration of about 5 - 10 mg/kg imetelstat or a pharmaceutically acceptable salt thereof once every three weeks; or (c) intravenous administration of about 5 - 9.4 mg/kg imetelstat or a pharmaceutically acceptable salt thereof once every four weeks. 33. Cantilena et al. additionally teach the administration of imetelstat to treat an AML cell line at dosages of 1.25 M, 2.5 M, 5 M, 10 M, 20 M and 40 M, which are equivalent to mg dosages of 5.76 mg, 11.53 mg, 23.0 mg, 46.1 mg, 92.2 mg, and 184.4 mg, when converted to mg (using the molecular weight of imetelstat of 4610 g/moL, as evidenced by PubChem, please see above), which overlaps the dose range of imetelstat of about 7 - 10 mg/kg required by step (a) of claim 19, and the range of about 5 - 10 mg/kg imetelstat required by step (b) of claim 19, and about 5 - 9.4 mg/kg required by step (c) of claim 19 (assuming a 62 kg human). Regarding the dose amount and frequency of administration of the imetelstat recited in steps (a) -(c) of claim 19, Cantilena et al. do not disclose the exact claimed amounts, but do overlap: in such instances even a slight overlap in range establishes a prima facie case of obviousness. MPEP 2144.05 states: In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). Even a slight overlap in range establishes a prima facie case of obviousness. In re Peterson, 65 USPQ2d 1379, 1382 (Fed. Cir. 2003). And, "A prior art reference that discloses a range encompassing a somewhat narrower claimed range is sufficient to establish a prima facie case of obviousness." In re Peterson, 315 F.3d 1325, 1330, 65 USPQ2d 1379, 1382-83 (Fed. Cir. 2003). >See also In re Harris, 409 F.3d 1339, 74 USPQ2d 1951 (Fed. Cir. 2005). 34. As such, one skilled in the art before the effective filing date of the claimed invention would have been motivated to optimize administration of imetelstat sodium for the treatment of AML in a subject in need thereof by employing at least one dose cycle of intravenous administration of about 5 mg/kg - 9.4 mg/kg imetelstat sodium once every four weeks. It would have been obvious to one of skill in the art before the effective filing date of the claimed invention to employ at least one dosage cycle of intravenous administration of about 5 mg/kg - 9.4 mg/kg imetelstat sodium once every four weeks, with a reasonable expectation of success. As such, claim 19 is prima facie obvious. Response to Arguments 35. Applicant traverses the previous obviousness rejection of claims 18 and 42-46 over Kuo et al. in view of Konopleva et al., and of claim 19 over Kuo et al. in view of Konopleva et al. further in view of Cantilena et al., and argues the following points: (i) Applicant argues that Kuo is solely cited for allegedly teaching the activity of the telomerase inhibitor imetelstat against acute myeloid leukemia (AML) cells, but fails to teach or suggest the administration of ABT-199 in combination with a telomerase inhibitor. Applicant alleges that there is no teaching in Kuo regarding a therapeutically effective amount of imetelstat. Applicant argues that Cantilena is cited for allegedly teaching the administration of imetelstat to treat an AML cell line at equivalent dosages of 5.76 mg, 11.53 mg, 23.0 mg, 46.1 mg, 92.2 mg, and 184.4 mg, when converted to mg (using the molecular weight of imetelstat of 4610 g/moL, as evidenced by PubChem), which overlaps the range of imetelstat of about 0.5 - 9.4 mg/kg. Applicant argues that Cantilena fails to teach or suggest the administration of ABT-199 in combination with the telomerase inhibitor. Applicant argues that Konopleva is related to ABT-199 monotherapy in patients with high risk relapsed/refractory AML and those unfit for chemotherapy. Applicant alleges that there is no teaching or suggestion in Konopleva that ABT-199 can be used in combination with other drugs, such as telomerase inhibitor, for combination therapy. 36. Applicant's arguments have been fully considered but they are not persuasive. As the prior art elements imetelstat and ABT-199 and their respective dose amounts are each previously taught for the treatment of AML or apoptosis of an AML cancer cell, one of ordinary skill in the art would have recognized that combining said elements would achieve a greater than additive effect in the treatment of AML. Nothing unobvious is seen in one skilled in the art treating AML in a patient in need thereof comprising the combined administration of imetelstat and ABT-199, in the dose amounts previously disclosed, with a reasonable expectation of success. (ii) Applicant argues that the claimed invention provides unexpected results that represent significantly more than the predictable use of prior art elements according to their established functions. Applicant argues that in the Specification at Example 3, imetelstat was tested in combination with ABT-199, at various concentrations of each, against AML tumor cells. Applicant alleges that a greater than additive effect of cell death is observed when imetelstat sodium is administered in combination with ABT-199 for 48 hrs across various concentration ranges for both drugs, resulting in a synergy score of 5.12 (see Table 19). Likewise, the results of various concentrations of the telomerase inhibitor imetelstat were tested in combination with various concentrations of ABT-199, against AML tumor cells for 96 hrs, resulting in a synergy score of 11.33 (see Table 22). 37. Applicant's arguments have been fully considered but they are not persuasive. In the instant case, Applicant has provided evidence that shows greater than additive results in the treatment of AML tumor cell lines following the administration of the specific combination of imetelstat sodium and ABT-199 at certain concentrations in Examples 1-5 in the Specification and Figures 1B, 2B, 5B, and 6B. However, although the evidence establishes greater than expected results, Applicant is reminded that “the objective evidence of nonobviousness must be commensurate in scope with the claims which the evidence is offered to support” (In re Clemens, 622 F.2d 1029 (CCPA 1980)). Thus, in In re Peterson, 315 F.3d 1325 (Fed. Cir. 2003), factual evidence demonstrating a greater than expected result from the addition of 2% of an ingredient did not evidence unexpected results for the entire claimed range of about 1-3% of the ingredient. Rather, the nonobviousness of a broader range or genus can only be established by evidence based on unexpected results of a narrower range or genus when one of ordinary skill in the art would be able to determine a trend in the exemplified data allowing said artisan to reasonably extend the probative value thereof. In re Kollman, 595 F.2d 48 (CCPA 1979). 38. In the instant case, the claims are not drafted commensurate in scope with the greater than expected results referenced above by Applicant and demonstrated in Figures 1B, 2B, 5B, 6B and 16. The instant claims are not limited to the administration of the specific combination of imetelstat or a pharmaceutically acceptable salt thereof and ABT-199 or a pharmaceutically acceptable salt thereof in dosages that are commensurate with the greater than additive effects shown in the Specification. The synergistic effects of the combined administration of imetelstat sodium and ABT-199, at the critical concentration(s) for each are demonstrated in the upper right quadrant of Table 19, wherein concentrations of ABT-199 are greater than or equal to 20 nM and concentrations of imetelstat sodium are greater than or equal to 25 mM (see also the upper right quadrant of Table 22, pages 61-65). 39. Since claims presently embrace a broader range than the combined features upon which Applicant relies, i.e., the dose-dependent synergistic effects of the combination of imetelstat or a pharmaceutically acceptable salt thereof and ABT-199 on AML in a subject in need thereof, the obviousness rejection is maintained. Conclusion 40. In conclusion, claims 18-22, and 42-47 are pending in the application. Claims 16, 17 and 20-22 are presently withdrawn as directed to a non-elected invention. Claims 18, 19 and 42-47 are rejected. No claim is presently allowable. 41. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. 42. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JANET L COPPINS whose telephone number is (571)272-0680. The examiner can normally be reached on Monday-Friday 8:30AM-5PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L Clark can be reached on 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JANET L COPPINS/Examiner, Art Unit 1628 /AMY L CLARK/Supervisory Patent Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

Show 3 earlier events
May 23, 2025
Non-Final Rejection mailed — §103, §112
Aug 19, 2025
Response Filed
Nov 28, 2025
Final Rejection mailed — §103, §112
Feb 27, 2026
Request for Continued Examination
Mar 09, 2026
Response after Non-Final Action
Mar 25, 2026
Non-Final Rejection mailed — §103, §112
Jun 10, 2026
Response Filed
Sep 09, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12728129
MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS
4y 8m to grant Granted Sep 08, 2026
Patent 12702150
Methods and Compositions for Slowing an Aging Process in a Human or an Animal
4y 11m to grant Granted Aug 11, 2026
Patent 12673955
NEW CRYSTAL FORM OF P-TOLUENESULFONATE SALT OF DIAZABICYCLIC COMPOUND AND PREPARATION METHOD THEREFOR
3y 4m to grant Granted Jul 07, 2026
Patent 12636297
BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF
4y 5m to grant Granted May 26, 2026
Patent 12611405
AGENT THAT INCREASES THE EXPRESSION OF THE BCL2-ASSOCIATED AGONIST OF CELL DEATH FOR THE TREATMENT OF CANCER
6y 7m to grant Granted Apr 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

6-7
Expected OA Rounds
72%
Grant Probability
99%
With Interview (+26.2%)
High
PTA Risk
Based on 934 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month